Stammdaten
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Unternehmen & Branche
| Name | Finch Therapeutics Group, Inc. |
|---|---|
| Ticker | FNCH |
| CIK | 0001733257 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 10,4 Mio. USD |
| Beta | 1,17 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2024-06-30 | 10-Q | 0 | -4,834,000 | -3.01 | 45,576,000 | 14,219,000 |
| 2024-03-31 | 10-Q | 0 | -3,876,000 | -2.41 | 50,092,000 | 19,038,000 |
| 2023-12-31 | 10-K | 107,000 | -74,754,000 | -46.59 | 55,373,000 | 22,886,000 |
| 2023-09-30 | 10-Q | 0 | -2,416,000 | -1.51 | 59,493,000 | 25,813,000 |
| 2023-06-30 | 10-Q | 0 | -6,950,000 | -4.33 | 66,857,000 | 27,894,000 |
| 2023-03-31 | 10-Q | 107,000 | -62,347,000 | -39.19 | 79,040,000 | 34,544,000 |
| 2022-12-31 | 10-K | 861,000 | -114,646,000 | -72.12 | 162,939,000 | 95,711,000 |
| 2022-09-30 | 10-Q | 138,000 | -40,371,000 | -25.38 | 187,968,000 | 120,866,000 |
| 2022-06-30 | 10-Q | 361,000 | -22,700,000 | -14.31 | 228,301,000 | 159,092,000 |
| 2022-03-31 | 10-Q | 354,000 | -24,567,000 | -0.52 | 204,633,000 | 179,791,000 |
| 2021-12-31 | 10-K | 18,532,000 | -58,160,000 | -1.48 | 225,369,000 | 202,224,000 |
| 2021-09-30 | 10-Q | 11,343,000 | -9,955,000 | -0.21 | 232,979,000 | 219,801,000 |
| 2021-06-30 | 10-Q | 2,830,000 | -15,169,000 | 250,328,000 | 228,193,000 | |
| 2021-03-31 | 10-Q | 3,553,000 | -13,981,000 | 265,951,000 | 239,457,000 | |
| 2020-12-31 | 10-K | 7,719,000 | -39,341,000 | 165,338,000 | -95,718,000 | |
| 2020-09-30 | 10-Q | 1,771,000 | -10,090,000 | -85,532,000 | ||
| 2020-06-30 | 10-Q | 2,349,000 | -8,259,000 | -75,510,000 | ||
| 2020-03-31 | 10-Q | 1,792,000 | -7,901,000 | -67,343,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.